MAY 14, 2020 7:52 PM PDT

Therapeutic for Gastrointestinal Tumors

WRITTEN BY: Nouran Amin

The FDA has approved ripretinib (Qinlock) which is the first drug for fourth-line treatment of advanced gastrointestinal stromal tumors (GIST). The therapeutic is approved for use in adults who have previously received treatment with 3 or more kinase inhibitor therapies, including imatinib, sunitinib, and regorafenib. When patients do not respond to these treatments, they may be prescribed Qinlock.

GIST results when abnormal cells form in the tissues of the gastrointestinal tract. These tumors most likely form in the stomach, small intestine, and large intestine.

Learn more about GIST, which affects roughly 6,000 adults annually in the United States:

“GIST is a complex disease and the majority of patients who initially respond to traditional tyrosine kinase inhibitors eventually develop tumor progression due to secondary mutations,” said Margaret von Mehren, MD, chief of sarcoma oncology and associate director for clinical research at Fox Chase Cancer Center.

Treatment for GIST using Qinlock was granted approval after findings of the INVICTUS study through the Fast Track designation and Priority Review by the FDA, in addition to the Breakthrough Therapy designation.

Some noted side-effects of Qinlcok use includes alopecia, fatigue, vomiting, and a variety of additional gastrointestinal complications. Treatment may also adversely affect a developing fetus during pregnancy and may be a risk for skin cancer, hypertension, and cardiac dysfunction.

“In the INVICTUS study, Qinlock has demonstrated compelling clinical benefit in progression-free and overall survival. Qinlock is well tolerated and is a crucial new therapy for these patients with a high unmet need.”

Source: AJMC

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 12, 2020
Technology
The Crossover of Virtual Reality and Drug Discovery
NOV 12, 2020
The Crossover of Virtual Reality and Drug Discovery
Researchers have recently developed a unique virtual reality (VR) tool that can help in drug development? Particularly, ...
NOV 26, 2020
Cannabis Sciences
Women More Likely than Men to Swap Prescription Medication for Cannabis
NOV 26, 2020
Women More Likely than Men to Swap Prescription Medication for Cannabis
The stigma around cannabis usage is fading as cannabis laws become increasingly lax. Now, researchers from DePaul Univer ...
DEC 01, 2020
Immunology
Scar-Free Healing Starts With Mobilizing the Immune System
DEC 01, 2020
Scar-Free Healing Starts With Mobilizing the Immune System
Thanks to a new hydrogel biomaterial developed by researchers at Duke University, we are one step closer to the holy gra ...
DEC 30, 2020
Neuroscience
Do Psychedelics Reduce Trauma from Racial Injustice?
DEC 30, 2020
Do Psychedelics Reduce Trauma from Racial Injustice?
Researchers from Ohio State University have found that a single positive experience on psychedelics may reduce stress, d ...
JAN 05, 2021
Drug Discovery & Development
Promising Epigenetic Treatment for Depression Works After One Dose
JAN 05, 2021
Promising Epigenetic Treatment for Depression Works After One Dose
Researchers affiliated with the University of Sao Paulo in Brazil have used epigenetic modulators to reduce stress-induc ...
JAN 05, 2021
Neuroscience
Synthetic Psychedelic Treats Depression Without Hallucinations
JAN 05, 2021
Synthetic Psychedelic Treats Depression Without Hallucinations
Psychedelics are receiving an increasing amount of attention- both in research and in the media- for their potential to ...
Loading Comments...